Top Stories News

Companies that have left it too late to implement their own solution will have to rely on support from providers, whose resources are already in high demand as the deadline approaches.

The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.

With only a month to go, it really is too late to start trying to develop an in-house solution.

Eight of the top ten pharma nations reporting improving market conditions.

Accepting more complexity and risk is key for those generics companies seeking competitive differentiation by diversifying their product portfolios.

Therapeutic ADC market expected to reach $4 billion by 2023.

Companies new to CPhI to showcase an exciting range of products and services ranging from electroceuticals to refrigerant alternatives.

While not quite an endangered species, the past fifteen years have not been easy ones for many European mould makers. Many, but not all, and IGS GeboJagema is a case in point – a case that shows the difference automation and focus can make. By Karen La...

The new Primary Care and China & Emerging Markets global business units are expected to launch at the beginning of 2019.

China is harmonizing to ICH standards at feverish pace and will force poor quality manufacturers out of market.

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.